A new target to treat cancer and Crohn's Disease


It has been announced by Cambridge Enterprise Limited, the commercialisation office of the University of Cambridge, that a licence agreement has been completed with Medarex, Inc. for the potential development by Medarex of a therapeutic drug which will target cancer and autoimmune diseases.

A team from the University of Cambridge has identified a cell surface marker that is expressed at high levels in certain cancer cells and in some tissues affected by autoimmune diseases such as Crohn’s disease but at lower levels in tissues unaffected by disease. This marker may provide a target for the potential development of novel antibody based-medicines to treat diseases in patients.
Medarex is a US based company specialising in the development of fully human antibody therapeutics.
The target was identified by Professor John Trowsdale, Dr Rob Eagle and Dr Louise Bacon in the University of Cambridge, Department of Pathology. Professor Trowsdale commented “Our initial studies on this protein have been fascinating and we are continuing our research on how it functions in health and disease. Meanwhile, we are delighted that Medarex plans to use its technology to generate antibodies to this target, which may lead to the development of novel therapeutics.”
Dr Andrew Walsh, Technology Manager at Cambridge Enterprise said “We are very pleased to have secured this agreement with Medarex. The company’s track record in developing antibody based therapies makes them a very attractive licensee.”

Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.

Cambridge Enterprise, University of Cambridge